Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Elucidating the role of Agl in bladder carcinogenesis by generation and characterization of genetically engineered mice.

Sottnik JL, Mallaredy V, Chauca-Diaz A, Ritterson Lew C, Owens C, Dancik GM, Pagliarani S, Lucchiari S, Moggio M, Ripolone M, Comi GP, Frierson HF, Clouthier D, Theodorescu D.

Carcinogenesis. 2019 Mar 12;40(1):194-201. doi: 10.1093/carcin/bgy139.

PMID:
30403777
2.

Metastatic cells are preferentially vulnerable to lysosomal inhibition.

Morgan MJ, Fitzwalter BE, Owens CR, Powers RK, Sottnik JL, Gamez G, Costello JC, Theodorescu D, Thorburn A.

Proc Natl Acad Sci U S A. 2018 Sep 4;115(36):E8479-E8488. doi: 10.1073/pnas.1706526115. Epub 2018 Aug 20.

3.

CD44: A metastasis driver and therapeutic target.

Sottnik JL, Theodorescu D.

Oncoscience. 2016 Dec 30;3(11-12):320-321. doi: 10.18632/oncoscience.335. eCollection 2016. No abstract available.

4.

An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression.

Ahmed M, Sottnik JL, Dancik GM, Sahu D, Hansel DE, Theodorescu D, Schwartz MA.

Cancer Cell. 2016 Sep 12;30(3):432-443. doi: 10.1016/j.ccell.2016.08.002. Epub 2016 Sep 1.

5.

Tumor-induced pressure in the bone microenvironment causes osteocytes to promote the growth of prostate cancer bone metastases.

Sottnik JL, Dai J, Zhang H, Campbell B, Keller ET.

Cancer Res. 2015 Jun 1;75(11):2151-8. doi: 10.1158/0008-5472.CAN-14-2493. Epub 2015 Apr 8.

6.

Osteocytes serve as a progenitor cell of osteosarcoma.

Sottnik JL, Campbell B, Mehra R, Behbahani-Nejad O, Hall CL, Keller ET.

J Cell Biochem. 2014 Aug;115(8):1420-9. doi: 10.1002/jcb.24793.

7.

Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.

Grivas PD, Daignault S, Tagawa ST, Nanus DM, Stadler WM, Dreicer R, Kohli M, Petrylak DP, Vaughn DJ, Bylow KA, Wong SG, Sottnik JL, Keller ET, Al-Hawary M, Smith DC, Hussain M.

Cancer. 2014 Mar 1;120(5):692-701. doi: 10.1002/cncr.28477. Epub 2013 Nov 18.

8.

Activation of the Wnt pathway through AR79, a GSK3β inhibitor, promotes prostate cancer growth in soft tissue and bone.

Jiang Y, Dai J, Zhang H, Sottnik JL, Keller JM, Escott KJ, Sanganee HJ, Yao Z, McCauley LK, Keller ET.

Mol Cancer Res. 2013 Dec;11(12):1597-610. doi: 10.1158/1541-7786.MCR-13-0332-T. Epub 2013 Oct 2.

9.

Parathyroid hormone-related protein inhibits DKK1 expression through c-Jun-mediated inhibition of β-catenin activation of the DKK1 promoter in prostate cancer.

Zhang H, Yu C, Dai J, Keller JM, Hua A, Sottnik JL, Shelley G, Hall CL, Park SI, Yao Z, Zhang J, McCauley LK, Keller ET.

Oncogene. 2014 May 8;33(19):2464-77. doi: 10.1038/onc.2013.203. Epub 2013 Jun 10.

10.

Integrin alpha2beta 1 (α2β1) promotes prostate cancer skeletal metastasis.

Sottnik JL, Daignault-Newton S, Zhang X, Morrissey C, Hussain MH, Keller ET, Hall CL.

Clin Exp Metastasis. 2013 Jun;30(5):569-78. doi: 10.1007/s10585-012-9561-6. Epub 2012 Dec 15.

11.

Understanding and targeting osteoclastic activity in prostate cancer bone metastases.

Sottnik JL, Keller ET.

Curr Mol Med. 2013 May;13(4):626-39. Review.

12.

Wnt and Wnt inhibitors in bone metastasis.

Sottnik JL, Hall CL, Zhang J, Keller ET.

Bonekey Rep. 2012 Jul 4;1:101. doi: 10.1038/bonekey.2012.101. eCollection 2012.

13.

Glycolysis inhibition by 2-deoxy-D-glucose reverts the metastatic phenotype in vitro and in vivo.

Sottnik JL, Lori JC, Rose BJ, Thamm DH.

Clin Exp Metastasis. 2011 Dec;28(8):865-75. doi: 10.1007/s10585-011-9417-5. Epub 2011 Aug 14.

PMID:
21842413
14.

The PCa Tumor Microenvironment.

Sottnik JL, Zhang J, Macoska JA, Keller ET.

Cancer Microenviron. 2011 Dec;4(3):283-97. doi: 10.1007/s12307-011-0073-8. Epub 2011 Jul 5.

15.

Induction of VEGF by tepoxalin does not lead to increased tumour growth in a canine osteosarcoma xenograft.

Sottnik JL, Hansen RJ, Gustafson DL, Dow SW, Thamm DH.

Vet Comp Oncol. 2011 Jun;9(2):118-30. doi: 10.1111/j.1476-5829.2010.00240.x. Epub 2010 Sep 13.

PMID:
21569197
16.

Association of blood monocyte and lymphocyte count and disease-free interval in dogs with osteosarcoma.

Sottnik JL, Rao S, Lafferty MH, Thamm DH, Morley PS, Withrow SJ, Dow SW.

J Vet Intern Med. 2010 Nov-Dec;24(6):1439-44. doi: 10.1111/j.1939-1676.2010.0591.x. Epub 2010 Sep 14.

17.

Minimally invasive assessment of tumor angiogenesis by fine needle aspiration and flow cytometry.

Sottnik JL, Guth AM, Mitchell LA, Dow SW.

Angiogenesis. 2010 Sep;13(3):251-8. doi: 10.1007/s10456-010-9182-0. Epub 2010 Aug 24.

18.

Interleukin-11 receptor alpha is expressed on canine osteosarcoma.

Sottnik JL, Thamm DH.

Vet Comp Oncol. 2010 Jun;8(2):96-102. doi: 10.1111/j.1476-5829.2010.00209.x.

PMID:
20579322
19.

An orthotopic, postsurgical model of luciferase transfected murine osteosarcoma with spontaneous metastasis.

Sottnik JL, Duval DL, Ehrhart EJ, Thamm DH.

Clin Exp Metastasis. 2010 Mar;27(3):151-60. doi: 10.1007/s10585-010-9318-z. Epub 2010 Mar 7.

PMID:
20213324
20.

Chronic bacterial osteomyelitis suppression of tumor growth requires innate immune responses.

Sottnik JL, U'Ren LW, Thamm DH, Withrow SJ, Dow SW.

Cancer Immunol Immunother. 2010 Mar;59(3):367-78. doi: 10.1007/s00262-009-0755-y. Epub 2009 Aug 23.

PMID:
19701748

Supplemental Content

Loading ...
Support Center